The NIH overhead cap died in court. The power grab did not.

I read court dockets the way you read a fire code: not for fun, but because you prefer buildings that stay standing. This week’s plot twist is quiet but decisive. The Trump administration let the deadline pass to ask the U.S. Supreme Court to revive an NIH policy that would have capped reimbursement for research “indirect costs” at 15%. No filing, no comeback. This particular cap is done.

What happened, in plain English

• February 2025: NIH issued a short notice announcing a 15% cap on indirect-cost reimbursement, effective the next business day.
• Lawsuits arrived immediately. A federal judge blocked the policy.
• January 2026: The First Circuit affirmed, leaving the cap dead unless the Supreme Court took it up.
• This week, DOJ let the Supreme Court deadline pass. The legal effort ends by default.

Universities and research hospitals can exhale. For now. But civics is never “problem solved.” It is “watch the next door,” because power that fails through the front entrance tends to try the air vents.

The Orwell check: “overhead” is doing political work

Call it “overhead” and people picture mahogany desks and catered seminars on “synergy.” Call it what it is, facilities and administrative costs, and you’re talking animal care, chemical waste disposal, patient privacy rules, cybersecurity, freezer alarms, and the compliance staff who keep trials legal and labs lit.

The rhetorical trick is that “indirect” sounds optional. But modern biomedical research is a regulated enterprise. Grants operate under federal rules with non-optional requirements, and the First Circuit opinion describes NIH’s longstanding architecture: documented direct costs plus documented indirect costs under a regulatory framework. The agency tried to rewrite that architecture through guidance, quickly.

The tradeoff: auditing versus the blunt instrument

I am not allergic to scrutiny. If someone pads expenses, investigate, negotiate harder, claw back improper charges, prosecute fraud if it is fraud. That is a scalpel.

An across-the-board cap imposed at speed is a meat cleaver. It ignores real differences among institutions, including costly compliance and safety operations, and treats physical realities like rent, utilities, and regulated-science infrastructure as if they were moral failings.

The liberty ledger: leverage, not just budgets

If NIH can unilaterally shrink the reimbursement that makes research hostable, the agency and the White House gain quiet leverage: you do not have to ban a field if you can make it financially impossible to run. The public, patients, and researchers lose stability, and researchers lose a smaller freedom too: pursuing questions without needing to flatter the current administration to keep the lights on.

The Paine test: restraint today, pressure tomorrow

Letting the Supreme Court deadline pass is restraint in one narrow sense. Good. But reporting and policy signals suggest the administration may try to reshape indirect-cost policy through government-wide grant rules rather than that NIH notice.

Courts did their job here. Now Congress should insist that any future changes happen in sunlight, through proper processes, with the guardrails NIH itself cites for FY2026. Otherwise we get governance by memo: temporary authority that never leaves.